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Background: Surface-expressed Na+/K+-ATPase (NaK) has been suggested to function as a non-canonical
cardiotonic steroid-binding receptor that activates multiple signaling cascades, especially in cancer cells. By contrast,
the current study establishes a clear correlation between the IC50 in vitro growth inhibitory concentration in human
cancer cells and the Ki for the inhibition of activity of purified human α1β1 NaK.
Methods: The in vitro growth inhibitory effects of seven cardiac glycosides including five cardenolides (ouabain,
digoxin, digitoxin, gitoxin, uzarigenin-rhamnoside, and their respective aglycone forms) and two bufadienolides
(gamabufotalin-rhamnoside and hellebrin, and their respective aglycone forms) were determined by means of the
MTT colorimetric assay and hellebrigenin-induced cytotoxic effects were visualized by means of quantitative
videomicroscopy. The binding affinity of ten of the 14 compounds under study was determined with respect to
human α1β1, α2β1 and α3β1 NaK complexes. Lactate releases and oxygen consumption rates were also
determined in cancer cells treated with these various cardiac glycosides.
Results: Although cardiotonic steroid aglycones usually display weaker binding affinity and in vitro anticancer
activity than the corresponding glycoside, the current study demonstrates that the hellebrin / hellebrigenin pair is
at odds with respect to this rule. In addition, while some cardiac steroid glycosides (e.g., digoxin), but not the
aglycones, display a higher binding affinity for the α2β1 and α3β1 than for the α1β1 complex, both hellebrin and
its aglycone hellebrigenin display ~2-fold higher binding affinity for α1β1 than for the α2β1 and α3β1 complexes.
Finally, the current study highlights a common feature for all cardiotonic steroids analyzed here, namely a dramatic
reduction in the oxygen consumption rate in cardenolide- and bufadienolide-treated cells, reflecting a direct impact
on mitochondrial oxidative phosphorylation.
Conclusions: Altogether, these data show that the binding affinity of the bufadienolides and cardenolides under
study is usually higher for the α2β1 and α3β1 than for the α1β1 NaK complex, excepted for hellebrin and its aglycone
form, hellebrigenin, with hellebrigenin being as potent as hellebrin in inhibiting in vitro cancer cell growth.
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A large proportion of cancer patients fail to respond to
conventional cytotoxic chemotherapy because of the
intrinsic resistance of cancer to pro-apoptotic stimuli
and/or the acquisition of multidrug resistance (MDR)
during chronic treatment. As emphasized by Pardo et al.
[1], the concept of ion channels and pumps as cancer
targets has recently gained considerable attention, and
the Na+/K+-ATPase (the Na/K pump, i.e., NaK) could be
targeted to combat chemoresistant cancers [2-4].
NaK is composed of α and β subunits. Four α and three
β subunits have been cloned with distinct tissue-specific
distribution and physiological functions [2-5]. The Na/K
pump maintains the concentration gradients of Na+ and
K+ ions across the surface membrane of animal cells by
exporting 3 Na+ ions and importing 2 K+ ions at the
expense of hydrolysis of a single ATP up to 100 times
each second [6]. However, a substantial amount of
surface-expressed NaK in certain types of cells has been
suggested to function as non-canonical cardiotonic
steroid-binding receptors [7] that form complexes with
caveolin-1, Src kinase and epidermal growth factor
receptor (EGFR) to activate multiple signaling cascades
[8-11] that are markedly different between normal and
cancer cells [2-4].
The most potent and selective NaK ligands, which bind
to NaK α subunits, are cardiotonic steroids represented by
two classes of compounds known as the cardenolides
(including digoxin and ouabain; Figure 1) and the
bufadienolides (including hellebrin; Figure 1) [2-5].
Digoxin has been used for decades to treat heart failure
due to its ability to increase the force of contraction
(inotropic effect) and reduce heart rate, but digoxin
remains a dangerous drug because it has a narrow
therapeutic window, and can lead to cardiac arrhythmias
[2-5]. Indeed, excessive NaK inhibition by digoxin
can cause calcium overload, which can in turn cause
arrhythmias [5]. The α2 isoform plays a more important
role in calcium handling in cardiac contraction compared
to the α1 and α3 isoforms, and digoxin displays moderately
higher selectivity for the α2 and α3 isoforms over the α1
isoform [5,10,12].
Digoxin has also been shown to have significant
therapeutic benefits in breast [13,14] and prostate
[15] cancers. However, the levels of expression of the
various α subunits have not been determined in breast and
prostate cancers. The NaK α1 subunit is overexpressed
in a significant proportion of cases in melanomas [16],
kidney cancers [17], non-small-cell lung cancers (NSCLCs)
[12] and glioblastomas [10]. In contrast, the NaK α3
subunit is overexpressed in a significant proportion of
colon cancers [18] and hepatocellular carcinomas [19].
Thus, while digoxin seems to be associated with promising
anticancer effects in breast [13,14] and prostate [15]cancers, the full anti-cancer potential of this drug has not
yet been addressed. It is necessary to analyze digoxin in
the cohorts of cancer patients enriched with the α3
isoform because of the preferential binding of digoxin
to the NaK α3 subunit over the α1 subunit [5,10,12]. In
contrast, more selective NaK α1 ligands are required to
combat those melanomas, glioblastomas, kidney cancers
and NSCLCs that overexpress the NaK α1 subunit. We
show here that hellebrin and, more surprisingly, its
deglycosylated form, hellebrigenin, display distinct in vitro
anticancer effects and NaK α-subunit-binding patterns
when compared to digoxin and other cardiotonic steroids.
The present study also shows that gamabufotalin-
rhamnoside displays more powerful in vitro anticancer
activity than any other cardiotonic steroids under study,




Ouabain (O3125), ouabagenin (O2627), digoxin (D6003),
digoxigenin (D9026), digitoxin (D5878) and gitoxigenin
(G4635) were obtained from Sigma-Aldrich NV/SA
(Bornem; Belgium). Hellebrin was isolated (at the
Dipartimento di Scienze Chimiche, Università di Napoli
Federico II, Italy) from Helleborus purpurascens ac-
cording to a modified procedure from Cioaca and Cucu
[20]. Gitoxin (ASB-00007232-005) was obtained from
ChromaDex Inc. (Miami, FL). Uzarigenin-rhamnoside
was isolated from Roupellina (Strophanthus) boivinii
according to a procedure described by Karkare et al.
[21], and was a gift from Prof. W. Schoner (Univ. Giessen,
Germany). In order to verify the structure of the compound
it was characterized at the Weizmann Institute by
1H- and 13C- NMR and High Definition, Q-TOF Mass
Spectrometric analysis. Uzarigenin was obtained from
Chemos Gmbh (Regenstauf, Germany). Hellebrigenin
was obtained from hellebrin hydrolysis (Department
of Pharmacognosy; University of Vienna, Austria).
Gamabufotalin-rhamnoside was isolated from different
Urginea species [22-24]; gamabufotalin was isolated
from toad venom of Bufo melanostictus [25]; both
were structure elucidated by B.K. (Department of
Pharmacognosy, University of Vienna). All compounds
under study were obtained with a purity > 95%. All
compounds were prepared in a 10-2M DMSO stock
solution and then diluted in PBS or water to carry out the
experiments.
Cancer cell lines
The histological types and origins of the eight human
cancer cell lines that were used for the MTT colorimetric
assay are detailed in the legend of Table 1. Two mouse






























































































































Figure 1 Chemical structures of the cardiotonic steroids under study. A: The characteristic unsaturated butyrolactone and alpha-pyrone
substructure of cardenolides and bufadienolides, respectively. The individual glycosylated B: cardenolides and C: bufadienolides under study differ
mainly in the hydroxylation pattern and the nature of the sugar moiety.
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http://www.molecular-cancer.com/content/12/1/33cancer cell line (ATCC code CRL-2638) and the B16F10
melanoma cell line (ATCC code CRL-6475). Both cell
lines were obtained from the American Type Culture
Collection (ATCC, Manassas, VA). A control cell line
(human NHDF fibroblasts) was obtained from PromoCell
(code c-12300; Heidelberg, Germany). The cell lines
detailed in Figure 2A are a generous gift from the
National Cancer Institute (NCI, Bethesda, USA) to Steven
Karlish’s lab.
Determination of in vitro growth inhibitory activity
The cancer cells were cultured in RPMI (Lonza, Verviers,
Belgium) medium supplemented with 10% heat-inactivated
fetal calf serum (Lonza). All culture media were
supplemented with 4 mM glutamine, 100 μg/mLgentamicin, 200 U/mL penicillin and 200 μg/mL
streptomycin (Lonza). The NHDF fibroblasts were
cultured in Lonza medium cc3132 KT FGM-2 BulletKit.
The overall growth level of the human cancer cell
lines was determined using a colorimetric MTT (3-
(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide,
Sigma, Belgium) assay as detailed previously [10,12,16].
Briefly, this test measures the number of metabolically
active (thus living) cells that are able to transform the yellow
MTT into the blue formazan dye via a mitochondrial
reduction involving succinate dehydrogenase. The amount
of formazan obtained at the end of the experiment
(measured by spectrophotometry) is directly proportional
to the number of living cells. The determination of the
optical density in the control compared to the treated cells
Table 1 In vitro growth inhibitory concentrations at 50% (IC50) in human cancer cells after three days of culture in the
presence of the drug of interest
Compounds IC50 (nM)
A549 U373 Hs683 T98G MCF-7 SKMEL-28 PC-3 HT-29 Mean ± SEM
Cardenolides
Ouabain* 37 ± 2 78 ± 1 34 ± 3 80 ± 3 100 ± 17 83 ± 13 63 ± 10 84 ± 8 70 ± 8
Ouabagenin* 866 ± 25 5,281 ± 250 1,902 ± 167 3,600 ± 36 4,011 ± 202 2,563 ± 183 2,708 ± 62 3,482 ± 19 3,052 ± 479
Digoxin* 60 ± 7 227 ± 42 51 ± 6 274 ± 17 363 ± 35 220 ± 26 215 ± 71 208 ± 20 202 ± 37
Digoxigenin* 395 ± 34 3,188 ± 129 794 ± 22 1,171 ± 99 5,321 ± 170 4,005 ± 116 3,880 ± 87 4,458 ± 83 2,902 ± 658
Digitoxin** 11 61 15 32 187 59 37 198 75 ± 26
Digitoxigenin** 92 369 79 166 2,134 2,495 298 230 733 ± 349
Gitoxin** 68 351 79 174 828 679 361 352 362 ± 96
Gitoxigenin** 1,715 4,477 653 3,589 5,193 > 10,000 3,964 4,403 > 4,249
Uzarigenin-rhamnoside** 45 247 38 38 469 222 77 41 147 ± 55
Uzarigenin** 3,169 7,918 2,252 5,138 > 10,000 > 10,000 6,281 6,439 > 6,025
Bufadienolides
Gamabufotalin-rhamnoside* 3 ± 1 6 ± 2 4 ± 1 7 ± 1 17 ± 5 18 ± 7 6 ± 1 8 ± 1 9 ± 2
Gamabufotalin* 7 ± 1 34 ± 1 14 ± 3 31 ± 8 40 ± 7 22 ± 1 22 ± 4 37 ± 3 26 ± 4
Hellebrin* 6 ± 1 41 ± 2 7 ± 1 30 ± 1 58 ± 12 40 ± 5 11 ± 1 27 ± 4 28 ± 7
Hellebrigenin* 3 ± 1 9 ± 1 6 ± 1 9 ± 1 42 ± 2 28 ± 9 18 ± 1 9 ± 1 16 ± 5
* the data were obtained from three independent experiments, with all experiments carried out in six replicates.
** the data were obtained from one experiment carried out in six replicates.
The human cancer cell lines were obtained from the American Type Culture Collection (ATCC, Manassas, VA), the European Collection of Cell Culture (ECACC,
Salisbury, UK), and the Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ, Braunschweig, Germany). The analyzed cell lines include the A549
NSCLC (DSMZ code ACC107); the U373 (ECACC code 89081403), T98G (ATCC code CRL-1690) and Hs683 (ATCC code HTB-138) glioma; the SKMEL-28 melanoma
(ATCC code HTB-72); the MCF-7 breast (DSMZ code ACC115); the PC-3 prostate (DSMZ code ACC465); and the HT-29 colon (ATCC code HTB-38) cancer models.
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of compounds on the growth of normal as well as cancer
cells in vitro.
Each experimental condition was performed in six
replicates.
MDR cancer cell lines
The following human cancer cell lines and their
chemoresistant sublines were used in this study: the
colon carcinoma cell line HCT-116 p53/wt and the p53
knock-out cell line HCT-116 p53/ko (generously donated
by B. Vogelstein, Johns Hopkins University, Baltimore,
MD, USA); the epidermal carcinoma-derived cell line
KB-3-1 and the ABCB1-overexpressing subline KB-C-1
(generously donated by D.W. Shen, Bethesda, USA); the
small cell lung carcinoma cell line GLC-4 and the
ABCC1- and LRP-overexpressing subline GLC-4/ADR
(from E.G. de Vries, Groningen, Netherlands); the ovarian
carcinoma cell line A2780 and the cisplatin resistant
subline A2780cis (purchased from Sigma-Aldrich); and
the promyelocytic leukemia cell line HL60 and the
mitoxantrone resistant subline HL60/mx (generously
donated by G. Harker, Salt Lake City, USA). All cell lines
were grown in RPMI 1640 supplemented with 10% fetal
bovine serum with the exception of the HCT-116 cells,
which were grown in McCoy’s medium with 10% serum.Binding affinity of cardiotonic steroids, inhibition of
activity of NaK isoforms
Expression of the human isoforms α1β1, α2β1 and α3β1
in Pichia pastoris (strain SMD1165) and purification of
the detergent-soluble isoform proteins, 3H-ouabain-binding
competitive displacement by other cardiotonic steroids on
P. pastoris membranes expressing human α1β1, α2β1, and
α3β1 isoforms, and analysis of the binding data was
performed as previously described [5]. 3H-ouabain binding
to yeast membranes (200–300 μg protein) was assayed at
37°C for 1 hour in a medium containing MOPS-Tris
10 mM, pH 7.2; MgCl2, 3 mM; Vanadate-Tris, 1 mM;
EGTA-Tris, 1 mM [26]. Binding of ouabain or competitive
displacement by other cardiac glycosides was assessed
by varying total concentrations of ouabain or other
cardiac glycosides at constant 3H-ouabain (between 1-2 nM
(specific activity) 30–40 Ci/mmol). K0.5 was calculated using
a one site inhibition model: B/BCG=0 = K0.5/([CG] + K0.5).
B refers to the 3H-ouabain bound at a particular concen-
tration of the cardiac glycoside [CG] and BCG=0 refers to
the 3H-ouabain bound at 1-2nM 3H-ouabain in the absence
of other cardiac glycosides. The KD was calculated from
K0.5 by taking into account ouabain-CG competition as
KD = K0.5/ (1 + [Ouf]/ KDOu). With KDOu values α1β1 9.2
nM, α2β1 21.5 nM and α3β1 11 nM, respectively [5]. At
1nM total ouabain, the values of 1 + [Ouf]/ KDOu were
AB
Figure 2 NaK alpha1-subunit and in vitro growth inhibition of
cancer cells. A: Correlation of Ki for inhibition of human α1β1 by
cardiac glycosides and the growth inhibition effects (IC50) of human
cancer cells; 1: digoxin; 2: hellebrin; 3: ouabain; 4: oleandrin; 5:
hellebrigenin; 6: gamabufotalin-rhamnoside. IC50 values are the
averages ± SEM of 4 experiments with 10 different human cancer
cell lines from the NCI60 library: ACHN (renal cell carcinoma); SF-268
and SNB-75 (glioma); MCF-7 (breast cancer); SKMEL-5 (melanoma);
HCT-116 and HT-29 (colon cancer); A549 (NSCLC); TK-10 (kidney
cancer); and Ovcar-3 and Ovcar-4 (ovarian cancer). In this
experiment, the IC50 values were determined after two days of
culture using the crystal violet assay [54]. B: Illustration of the IC50
in vitro growth inhibitory concentration (MTT colorimetric assay; Y
axis) as opposed to the mRNA levels (by means of quantitative RT-
PCR as detailed in [10]) of the NaK α1 subunit in five human cancer
cell lines, including Hs683 oligodendroglioma (207 mRNA copies /
μg cDNA); T98G GBM (911 mRNA copies / μg cDNA); A549 NSCLC
(1,450 mRNA copies / μg cDNA); U373 GBM (2,091 mRNA copies /
μg cDNA); and PC-3 prostate adenocarcinoma (5,337 mRNA copies /
μg cDNA) cells. The IC50 growth inhibitory concentrations that are
reported in Figure 2B are from Table 1.
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glycoside was estimated in 3 separate experiments.
The inhibition of NaK activity of the purified
detergent-soluble α1β1, α2β1, and α3β1 complexes by
cardiotonic steroids and an analysis of the inhibition data
(Ki values) were also performed as previously described
[5]. The inhibitors were added to the recombinant enzyme
(0.08–0.2 μg of protein) in 400 μl of reaction medium
containing 130 mM NaCl, 5 mM KCl, 3 mM MgCl2,
25 mM histidine, pH 7.4, 1 mM EGTA, 0.01 mg/ml SOPS,
0.001 mg/ml cholesterol, and 0.005 mg/ml C12 E8 in48-well plates. The reaction (37°C for 1 h) was started
by the addition of 1mM ATP. Pi release was mea-
sured with a malachite green dye to detect the
phosphor-molybdate (Pi Color Lock, Innova Biosciences).
The percent inhibition V /V0 was calculated for each
cardiac glycoside concentration, and Ki values were
obtained by fitting the data to the function V /V0 =Ki /
([CG] +Ki ) (using Kaleidagraph). V0 and V represent the
control rate and rate of NaK-ATPase activity at particular
concentrations of cardiac glycosides, [CG], respectively.
Average KD or Ki values ± SEM for each isoform were
calculated. Statistical significance was calculated by the
unpaired Students t-test. P values <0.05 were considered
significant.
Lactate release and O2 consumption rate
For enzymatic determination of lactate production,
confluent tumor cells were incubated with 10 mM
glucose for 24 hours. Culture medium was then filtered
through centrifugation columns with a 10 KDa cutoff, and
L-lactate concentrations were determined on an ISCUSflex
analyzer (CMA Microdialysis AB, Solna, Sweden). O2
consumption was determined using the MitoXpress assay
according to the manufacturer’s instructions (LuxCell
Biosciences, Cork, Ireland). Briefly, after adding the oxygen
probe to tumor cells cultured for 24 hours in 96-well
microplates with or without the tested compounds, the
wells were sealed with mineral oil, and respiration was
evaluated using time-resolved fluorescent plate readers.
Under these conditions, O2 depletion was translated into
an increase in probe phosphorescence signal, and the slope
of this signal was used to derive the O2 consumption rate.
Results
In vitro growth inhibitory effects of glycosylated versus
non-glycosylated forms of cardenolides and
bufadienolides in human cancer cells
In general, cardenolides and bufadienolides share a
steroid backbone, but these compounds differ from
each other on the basis of an unsaturated butyrolactone
(cardenolides) versus an α-pyrone (bufadienolides) moiety
(Figure 1A). The chemical structures of the cardenolides
and bufadienolides under study are illustrated in Figures 1B
and 1C, respectively. Only the glycosylated forms
(glycosides) of each cardiotonic steroid under study are
represented in Figure 1. The aglycones (Table 1) correspond
to the compounds without the sugar moiety.
Of the five cardenolides analyzed, gitoxin appeared to
be the least potent cardenolide in terms of growth
inhibitory activity of human cancer cells (Table 1). In
contrast, the two bufadienolides, gamabufotalin-rhamnoside
and hellebrin, appeared to be much more potent than
the cardenolides in terms of in vitro growth inhibition
of human cancer cells (Table 1).
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the literature, most cardiotonic steroid aglycones
displayed weaker in vitro growth inhibition than the
corresponding glycosides (Table 1). This was observed
clearly for the cardenolides (ouabain / ouabagenin and
digoxin / digoxigenin) and also for the bufadienolide pair
gamabufotalin-rhamnoside / gamabufotalin (mean IC50 ±
SEM: 9 ± 2 versus 26 ± 4 nM, p = 0.02). However, one clear
exception was noticed with hellebrin and hellebrigenin
(Table 1), for which the aglycone was not less effective
than the glycoside. We observed a tendency for lower
values of IC50 for hellebrigenin (mean IC50 ± SEM: 16 ± 5
nM) compared to hellebrin (mean IC50 ± SEM: 28 ± 7
nM), although the difference was not statistically signifi-
cant (also see the data in Table 2 and Figure 3).
Whether the genetic profiles (mutations) of the cell lines
under study influence the cardiotonic steroid-mediated
in vitro growth inhibition remains to be determined. The
present study however reveals that p53 status does not
influence cardiotonic steroid-mediated effects on in vitro
growth rates of human cancer cells as detailed below.
A non-cancerous control cell line, i.e. NHDF fibroblasts,
was used to analyze the in vitro growth inhibitory
effects of gamabufotalin-rhamnoside / gamabufotalin
and hellebrin / hellebrigenin. The data obtained were
gamabufotalin-rhamnoside: 1,840 nM; gamabufotalin: >
10,000 nM; hellebrin: > 10,000 nM, and hellebrigenin: >
10,000 nM. Thus, these four compounds display weaker
growth inhibitory effects in normal fibroblasts than in
cancer cells, as already observed previously with other
cardiotonic steroids [10,12].
All of the compounds described in Table 1 were also
assayed for in vitro growth inhibitory activity in two
mouse cancer cell lines: the CT26 colon cancer and the
B16F10 melanoma cell lines. Except for gamabufotalin-
rhamnoside, all of the compounds displayed IC50 growth
inhibitory concentrations higher than 10,000 nM (data
not shown). Rodent NaK shows a roughly 1,000-fold
lower affinity for ouabain compared to human NaK
(detected as Ki for inhibition of activity of 100 and 0.1
μM, respectively). This feature is caused by two mutations
(human-rat Q117R and N128D) in the extracellular loop
between TM1 and TM2 in murine α1 compared to
human α1, which accounts for the low ouabain-binding
affinity of the rodent pump and the approximately 1,000-
fold weaker sensitivity of murine cancer cells to the
growth inhibitory effects of cardiotonic steroids [2]. Yang
et al. [27] demonstrated that the relative lack of the NaK
α3 subunit in rodent cancer cells may also account for
their unresponsiveness to cardiotonic steroids, but Lin
et al. [28] recently emphasized the importance of the NaK
α1 subunit in tumor growth and cancer cell survival.
Gamabufotalin-rhamnoside displayed IC50 concentrations
of 0.9 μM in CT26 colon cancer cells and 0.7 μM inB16F10 melanoma cells, which are concentrations that are
about one hundred times lower than those observed in
human cancer cells (Table 1).
Hellebrin and hellebrigenin overcome apoptosis-
resistance in cancer cells
Of the eight cancer cell lines reported in Table 1, we
have experimental evidence of various levels of resistance
of A549 NSCLC cells [29,30], U373 GBM cells [10,31]
and SKMEL-28 melanoma cells [32] to pro-apoptotic
stimuli. In the same manner, we have experimental
evidence of sensitivity to pro-apoptotic stimuli for
Hs683 oligodendroglioma cells [31,33], and MCF-7
breast cancer [34] and PC-3 prostate cancer [34] cells.
The data in Table 1 indicate that the various cardenolides
and bufadienolides used in this study (including
hellebrigenin) display similar in vitro growth inhibitory
activity in cancer cells that display sensitivity versus those
that display certain levels of resistance to pro-apoptotic
stimuli.
Hellebrin and hellebrigenin overcome MDR resistance in
cancer cells
Many ATP-binding cassette (ABC) transporters are
implicated in the MDR phenotypes of cancer cells
[35,36]. Therefore, hellebrin and hellebrigenin were
assayed in various ABC models of MDR cancer cells, as
detailed in Figure 4.
First, Figure 4A confirms the data from Table 1. Indeed,
hellebrigenin and hellebrin (data not shown) display
similar in vitro growth inhibitory activity in p53 wild-type
versus p53KO human HCT-116 colon cancer cells.
Hellebrigenin and hellebrin (data not shown) are equally
active in several MDR cancer cell models with chemother-
apy resistance based on the overexpression of ABC-
transporters and/or altered glutathione metabolism. Thus,
the strongly ABCC1- and LRP-overexpressing small cell
lung cancer GLC4/ADR (Figure 4B) and the colchicine-
selected, ABCB1-overexpressing, HeLa cell subclone KB-
C-1, were equally sensitive against hellebrigenin as their
parental cell lines (Figure 4C). Additionally, neither cis-
platin resistance based on altered glutathione metabolism
and enhanced DNA repair (Figure 4D) nor mitoxantrone
resistance caused by alterations of topoisomerase II
(Figure 4E) conferred reduced sensitivity to hellebrigenin.
Hellebrin and hellebrigenin are cytotoxic compounds
Computer-assisted phase contrast microscopy (quantitative
videomicroscopy) analyses were used to morphologically
visualize the effects induced by hellebrin (data not shown)
and hellebrigenin (Figure 5) in human U373 GBM cells.
Hellebrigenin was assayed in U373 GBM cells at the IC50
growth inhibitory concentration of 10 nM, which was
determined by the MTT colorimetric assay (Table 1).
Table 2 NaK alpha-subunit-binding affinity profiles for various cardenolides and bufadienolides (KD ± SEM)
Compounds Affinity (nM) Selectivity
α-1 α-2 α-3 α-1 / α-2 α-1 / α-3
Cardenolides
Ouabain 50 ± 10 70 ± 12 50 ± 7 0.7 1.0
Digoxin 104 ± 11 25 ± 4 27 ± 2 4.2 3.9
Uzarigenin-rhamnoside 90 ± 20 96 ± 7 122 ± 9 0.9 0.7
Uzarigenin 1,100 ± 120 883 ± 56 1,278 ± 142 1.3 0.9
Gitoxin 123 ± 8 85 ± 3 108 ± 17 1.5 1.1
Gitoxigenin 500 ± 90 1,180 ± 190 1,050 ± 100 0.4 0.5
Bufadienolides
Gamabufotalin-rhamnoside 30 ± 7 36 ± 10 17 ± 2 0.8 1.8
Gamabufotalin 243 ± 48 247 ± 30 236 ± 14 1.0 1.0
Hellebrin 86 ± 18 218 ± 52 175 ± 20 0.4 0.5
Hellebrigenin 103 ± 19 198 ± 51 191 ± 23 0.5 0.5
*The data were obtained from three independent experiments.
*The data for uzarigenin, uzarigenin-rhamnoside, gitoxigenin and gitoxin are from Katz et al. [5] and are included here.
*Ouabain binding affinities for the three isoforms appear lower than analyzed previously [5]. The lower values in [5] are the result of full Scatchard analysis for
ouabain which excludes all non-specific binding. The selectivity is the same even though the absolute values of KD are higher. All the experiments were done in
the same way, e.g. we have left all the values obtained in the displacement experiments.
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h of U373 cell treatment with 10 nM hellebrigenin, and
this effect was sustained up to 32–40 h after treatment
(Figure 5). Then, between 45–50 h, U373 GBM cells
began to die, and, in accordance with the MTT assay-
related data, approximately 50% of the U373 GBM cells
died after 72 h of treatment with 10 nM hellebrigenin
(Figure 5). These morphological analyses revealed that
hellebrigenin is a cytotoxic compound and not a cytostatic
one. Similar results were observed with respect to
hellebrin (data not shown).
Previous experiments that were carried out with the
19-hydroxy-2″-oxovoruscharin cardenolide pointed to
vacuolization processes in human A549 NSCLC cells
[30] and U373 GBM cells [10] that were similar to the
vacuolization displayed by hellebrigenin in human U373
GBM cells (Figure 5). These vacuolization processes
induced by 19-hydroxy-2″-oxovoruscharin led to sustained
and irreversible autophagy-related cell death in U373 GBM
cells [10] and to lysosomal membrane permeabilization-
related cell death in A549 NSCLC cells [30].
Low concentrations of bufadienolides inhibit oxidative
metabolism of human HT-29 colon cancer cells
The vacuolization processes reported in the previous
section with respect to 19-hydroxy-2″-oxovoruscharin
cardenolide in human A549 NSCLC [30] and U373
GBM [10] were paralleled by marked decreases in intra-
cellular ATP concentration ([ATP]i) in these cells [10,12],
while much weaker effects were observed in normal cells
[10,12]. Therefore, we analyzed the effects induced by four
cardenolides and four bufadienolides (including hellebrin
and hellebrigenin) on glycolysis and O2 consumption ratesin human HT-29 colon cancer cells. The preliminary
data (not shown) indicated that the HT-29 cell line
exhibited both glycolytic (glucose to lactate) and oxidative
(glucose to CO2) metabolism. While cardenolides and
bufadienolides did not alter the glycolytic flux as determined
by the measurements of lactate release in the extracellular
medium (Figure 6A), each compound significantly (P < 0.01)
influenced cell respiration (Figure 6B). The O2 consumption
rate was significantly reduced following treatment with
digoxin, ouabain, hellebrin and gamabufotalin-rhamnoside
at the IC50 in vitro growth inhibition of each compound
(as determined in the MTT assay). A trend to a
higher activity of the glycosides versus aglycones was
also observed. Of note, these measurements were obtained
after 24 h (Figure 6), a delay for which the confounding
effects of cell death could be excluded (Figure 4).
Characterization of the binding affinity and inhibitory
potential of cardiotonic steroids for human NaK subunits
Table 2 details the binding affinity and selectivity of various
cardenolides and bufadienolides for the human α1β1,
α2β1 and α3β1 NaK complexes measured as competitive
inhibition for 3H-ouabain-binding on yeast membranes
expressing the different isoforms [5,26]. These data
confirm the recent observation that digoxin displays
3- to 4-fold higher binding activity for human α2β1
and α3β1 than for α1β1, while ouabain displays similar
binding affinities for the three NaK complexes (Table 2)
[5]. The data in Table 2 also show that gamabufotalin-
rhamnoside shows a much higher affinity compared to
gamabufotalin (aglycone), but no subunit selectivity of the
aglycone. These data are compatible with the conclusion
that the sugar determines the isoform selectivity [5].
Figure 3 Inhibition of purified human α1β1 Na+/K+-ATPase by the glycoside (closed circles) and aglycone (open circles) pairs of A:
hellebrin/hellebrigenin and B: ouabain/ouabaigenin. (panel B) Solid lines are the fitted curves for a one site fitted model (see Materials and
Methods).The curves represent the averages of two experiments in duplicates.
Moreno Y Banuls et al. Molecular Cancer 2013, 12:33 Page 8 of 14
http://www.molecular-cancer.com/content/12/1/33The data from Table 2 point to an unusual feature of
hellebrin- and hellebrigenin-binding, which is that there
is no difference in affinity between the glycoside and
aglycone forms. There also appears to be a moderate
selectivity for the α1 compared to the α2 and α3 subunits
of both hellebrin and hellebrigenin, but some of the
differences are not significant. This unusual feature of
hellebrin- and hellebrigenin-binding detected in the
3H-ouabain displacement assays was confirmed in assays
of the inhibition of NaK activity of purified human α1β1
(Figure 3). Strikingly, hellebrigenin was more effective
than hellebrin in this inhibition assay (Ki 46 ± 6 and 103 ± 7
nM, respectively), whereas inhibition by ouabain and
ouabagenin showed the characteristic effect of a lower Ki
for the glycoside (Ki 97 ± 5 and 721 ± 70 nM, respectively).
A comparison of the inhibition of NaK activity of all
of the purified complexes showed no selectivity for either
hellebrin or hellebrigenin, while hellebrin and hellebrigenin
nevertheless displayed a two times higher affinity for α1β1
than for α2β1 or α3β1 complexes (Table 2).
Figure 2A indicates a strong linear correlation between
the in vitro IC50 growth inhibitory concentrations of
various cardiotonic steroids (ouabain, digoxin, hellebrin,
hellebrigenin, gamabufotalin rhamnoside, and oleandrin)
and the Ki for inhibition of the purified human NaK
α1β1 complex (IC0.5 = 0.354 x Ki - 0.170; r = 0.98). By
contrast, Figure 2B also reveals that there is no correlation
between these IC50 growth inhibitory concentrations and
the levels of α1 expression (determined at the level of
mRNA by means of quantitative RT-PCR). Together,
these observations imply that the IC50 values for growthinhibition by the different compounds are a consequence
of binding to and inhibition of the pump.Discussion
The Na/K pump maintains the concentration gradients of
Na+ and K+ ions across the surface membrane of animal
cells [6], and a substantial amount of surface-expressed
NaK, especially in cancer cells, has been suggested to func-
tion as non-canonical cardiotonic steroid-binding receptors
[7] that activate multiple signaling cascades [8-11].
Multiplex gene expression analysis demonstrated a
decade ago that various cardiotonic steroids inhibit prostate
target genes [37]. Several studies have demonstrated
that various cardiotonic steroids are able to sensitize
apoptosis-resistant cancer cells to pro-apoptotic stimuli
[38-40] and directly induce apoptosis in lymphoma [41]
and leukemia [42] cells. Cardiotonic steroids can also
induce cancer cell death through Src- or MAPK-mediated
inhibition of p53 expression [43], the inhibition of general
protein synthesis [44], the inhibition of HIF-1a synthesis
[45], sustained and irreversible autophagy [10,46] and
lysosomal membrane permeabilization [30].
Some cardiotonic steroids are also able to overcome
the MDR phenotype. Indeed, while ouabain activates the
MDR phenotype [47], 19-hydroxy-2″-oxovoruscharine
[48] and the hellebrin / hellebrigenin pair (Figure 4) display
similar and marked anticancer activity in chemosensitive
versus MDR cancer cells.
Thus, cardiotonic steroids display pleotropic anticancer
effects, and we recently reviewed all of the patents filed
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Figure 4 Impact of different MDR mechanisms on the cytotoxicity of hellebrigenin. The different drug-resistant cancer cell models (as
indicated) were treated for 72 hours with hellebrigenin (left panels) and with the respective drugs affected by the indicated resistance
mechanisms as positive controls (right panels). Viability was determined using a 3-(4,5-dimethythiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
colorimetric assay. Each assay was carried out in six replicates. The various cell lines used are A: the colon carcinoma cell line HCT-116 p53/wt
and the p53 knock-out cell line HCT-116 p53/ko; B: the small cell lung carcinoma cell line GLC-4 and the ABCC1- and LRP-overexpressing subline
GLC-4/ADR; C: the epidermal carcinoma-derived cell line KB-3-1 and the ABCB1-overexpressing subline KB-C-1; D: the ovarian carcinoma cell line
A2780 and the cisplatin resistant subline A2780cis; E: the promyelocytic leukemia cell line HL60 and the mitoxantrone resistant subline HL60/mx.
Cells were not starved during the experiments.
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http://www.molecular-cancer.com/content/12/1/33in this field, along with their potential applications in
oncology [49].
We previously reported that the 19-hydroxy-2″-
oxovoruscharin cardenolide induced marked decreases
in [ATP]i in various cancer cell types, while much weaker
effects were observed in normal cells [10,12]. This
observation was confirmed in the present study with








Figure 5 Computer-assisted phase-contrast microscopy (quantitative
treated with 10 nM hellebrigenin for 72 h. The squares on the left-hand
aspects of the U373 GBM cells on the right-handed images at a higher ma
Cells were not starved during the experiments. The images provided here
experimental condition.hellebrin / hellebrigenin. We provide evidence in this
study that the previously observed drop in intracellular
ATP in tumor cells exposed to cardiotonic steroids is
unlikely to arise from an alteration in the glycolytic flux.
The extent of glucose-to-lactate conversion remained
unaltered in HT29 colon cancer cells treated either with
cardenolides or bufadienolides. Instead, we found a
dramatic reduction in the oxygen consumption rate invideomicroscopy) illustrations of human U373 glioblastoma cells
ed panel of images (0 – 32 – 48 h) highlight the morphological
gnification, with the appearance of marked vacuolization processes.
































































































































Figure 6 Metabolic profiling of human HT29 colon cancer cells
treated with cardiotonic steroids. A: Extracellular lactate
concentrations and B: O2 consumption rates in HT29 cancer cells
treated with the indicated compounds at their IC50 in vitro growth
inhibitory concentrations (see Table 1). The data (mean ± SEM from
triplicates) are expressed in mM lactate accumulated in the
extracellular medium after 24 hours and arbitrary units derived from
time-resolved fluorescent signal.min-1.
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http://www.molecular-cancer.com/content/12/1/33cells treated with cardenolides and bufadienolides,
reflecting a direct impact on the mitochondrial oxidative
phosphorylation. While these effects on cell respiration
were quite similar for each compound tested, it should be
emphasized that bufadienolides (glycosylated or not)
were used at a concentration in the low nanomolar range
(10–30 nM), while cardenolides were used at concentra-
tions ~3-fold (ouabain), 10-fold (digoxine) and 150-fold
higher (ouabagenin, digoxigenin). This observation
again supports the specific profile of bufadienolides andidentifies tumor cell oxidative metabolism as a major
target of these drugs.
The glycosylation patterns of cardiotonic steroids
markedly influence their anticancer activity profiles. For
example, Langenhan et al. [50] demonstrated that the
glycorandomization of digitoxin leads to analogs that
display significantly enhanced anticancer activity and
tumor specificity when compared to digitoxin. In addition,
changes in NaK expression dictate the growth regulatory
effects of ouabain on cells [51]. In the current study, the
quantitative determination of α1, α2 and α3 subunits at
the mRNA level in the various cancer cell lines that were
used clearly indicated that all of the cell lines expressed
the α1 subunit, though in a heterogeneous manner
(Figure 2B), but did not express the α2 or α3 subunits (or
they expressed the α3 subunit in very low amounts) (data
not shown).
Table 2 includes previously published data [5] and
shows that ouabain could display weak selectivity for the
α1 subunit, while digoxin shows a 3- to 4-fold selectivity
for α2/α3. The other cardenolides, uzarigenin and
gitoxin, do not show isoform selectivity, although the
glycosides have much higher affinities compared to
the aglycones. For the bufadienolide gamabufotalin /
gamabufotalin-rhamnoside pair, the rhamnoside appears
to show marginal selectivity for α1 when compared to α2
but not to α3. There is also a clear difference in that the
glycoside shows a much higher affinity than the aglycone
(Table 2). By contrast, the hellebrin / hellebrigenin pair is
anomalous in that the glycoside does not show a
higher affinity for 3H-ouabain displacement compared
to the aglycone, and in NaK inhibition assays the
aglycone is even somewhat superior to the glycoside
(Figure 3). Of all the cardiotonic steroids analyzed, the
hellebrin / hellebrigenin pair displayed the highest
selectivity for the NaK α1 subunit at an approximately
2 times higher affinity for the α1 than for the α2 and α3
subunits (Table 2).
The features of binding and inhibition of the human
α1β1 complex of the different cardiac glycosides are
reflected in the IC50 concentrations for growth inhibition.
A positive correlation was shown between the IC50 for
growth inhibition and Ki for inhibition of the purified
α1β1 complex, and there is no evidence for a pattern
typical of inhibition of α2 or α3 (Figure 2A). For example,
digoxin shows a higher Ki and IC50 compared to ouabain.
This is typical for α1, whereas digoxin should show a
lower Ki and IC50 than ouabain in the cases of α2 and α3
subunits [5]. The data for the bufadienolides are consistent
with these conclusions, especially the conclusion that a
lower Ki for α1β1 is associated with a lower IC50 for
growth inhibition. The anomaly in binding and inhibition
occurs with the hellebrin / hellebrigenin pair, a feature
that may be related to the fact that the second sugar in
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http://www.molecular-cancer.com/content/12/1/33hellebrin is glucose. In systematic studies, it has been
found that glucose is not an optimal glycoside derivative
for the binding or inhibition of renal NaK α1β1 [52,53]. It
has also been previously shown that the relative effects of
glycoside and aglycone on Ki for inhibition of the renal
NaK vary markedly in the function of different cardiac
steroids [54]. The parallel behavior between binding and
inhibition of α1β1 versus cancer cell growth inhibition is
also observed for the hellebrin / hellebrigenin pair. The
findings that mouse cancer cells display high IC50 values
for growth inhibition by different cardiac glycosides and
that the growth effects of gamabufotalin-rhamnoside are
in the μM range (compared to the nM range for the
human cancer cells) also demonstrate the association of
cancer cell growth inhibition and inhibition of the low
affinity cardiac glycoside-binding rodent α1β1 complex.
The gamabufotalin-rhamnoside is therefore a useful tool
to check this association in rodent cells because even a
“low affinity” effect is in the μM concentration range.
Conclusions
The clear correlation between the IC50 growth inhibitory
concentration and Ki for inhibition of NaK activity of
purified human α1β1 suggests that the inhibition of
α1β1 is the first step in the cancer growth inhibition
effects of cardiac glycosides, provided that NaK α3β1 is
not more present in vitro (as in the case of the current
study). This feature is also true for some cancer types
that overexpress the NaK α1β1 but not the α3β1 complex,
such as gliomas [10], melanomas [16], NSCLCs [12] and
renal cell carcinomas [17]. Anomalies in the expected
pattern of behavior of the glycoside and aglycone, such as
in the case of hellebrigenin and hellebrin, further
strengthen this correlation. Thus, hellebrigenin, with its
free C3 position, might be derivatized into novel analogs
to increase the selectivity for the α1 subunit and make
these original optimized hellebrigenin analogs novel
weapons to combat those gliomas, melanomas, NSCLCs
and renal cell carcinomas that overexpress this α1 subunit.
While the mechanism of the cytotoxic effects of cardiac
glycosides is not yet entirely deciphered [2,4,55], the
current study highlights a common feature for all of the
cardiotonic steroids we analyzed, including cardenolides
and bufadienolides, which is a dramatic reduction in
the oxygen consumption rate in cardenolide- and
bufadienolide-treated cells. These data suggest a direct im-
pact on mitochondrial oxidative phosphorylation. In this
respect, it is also interesting that the cardiotoxicity of oua-
bain appears to be associated with the disruption of mito-
chondrial Ca2+ handling and NAD/NADH ratios [56-58].
This feature could explain why i) cardiotonic steroids are
more toxic with respect to cancer than normal cells and
ii) certain cardiotonic steroids are able to overcome the
intrinsic resistance of cancer cells to pro-apoptoticstimuli without activating the MDR phenotype, even if
these cardiotonic steroids are cytotoxic, such as the
hellebrin / hellebrigenin pair (the current study) or 19-
hydroxy-2″-oxovoruscharine [48].
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